Mean plasma glucose concentrations over time with BAQSIMI
* A randomized, multicenter, crossover noninferiority trial was conducted in adult patients with Type 1 diabetes. Hypoglycemia was induced with intravenous insulin and treated by 3 mg intranasal glucagon or 1 mg intramuscular glucagon. Plasma glucose was measured after each treatment was given.
Nasally administered BAQSIMI demonstrated comparable efficacy to glucagon for injection in adult patients with Type 1 diabetes
Treatment success for BAQSIMI and glucagon for injection*
Treatment success was defined as the percentage of patients with either an increase in blood glucose to ≥3.9 mmol/L or an increase of ≥1.1 mmol/L from blood glucose nadir within 30 minutes.
Nadir is defined as minimum glucose measurement at the time of or within 10 minutes after glucagon administration. The mean nadir blood glucose was 2.5 mmol/L for BAQSIMI and 2.7 mmol/L for injectable glucagon.
Nasal congestion does not impact the absorption of BAQSIMI
* Study IGBC was a randomized, multicenter, open-label, 2-period, crossover study in adult patients with Type 1 diabetes (n=77) that compared the efficacy of a single 3 mg dose of BAQSIMI versus 1 mg injectable glucagon for treatment of hypoglycemia induced by intravenous insulin with a target blood glucose of <2.8 mmol/L. The primary efficacy measure was the proportion of patients achieving treatment success.
Click here to download the full study publication